API | norbuprenorphine

norbuprenorphine Report issue

Small molecule Experimental

AACT MeSH PubChem

Active Ingredient History

NOW

Norbuprenorphine is a major active metabolite of the opioid modulator buprenorphine. It is a μ-opioid, δ-opioid, and nociceptin receptor full agonist, and a κ-opioid receptor partial agonist. In rats, unlike buprenorphine, norbuprenorphine produces marked respiratory depression but with very little antinociceptive effect. In explanation of these properties, norbuprenorphine has been found to be a high affinity P-glycoprotein substrate, and in accordance, shows very limited blood-brain-barrier penetration. ^Wikipedia

Chemistry

SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1)[C@H]2O5
InChIKey: YOYLLRBMGQRFTN-IOMBULRVSA-N
Mol. Mass: 413.56
ALogP: 3.29 Partition coefficient
ChEMBL Molecule:
norbuprenorphine

More Chemistry

Pharmacology

Mechanisms of Action:
- Delta-type opioid receptor (Homo sapiens) ^UniProt
- Mu-type opioid receptor (Homo sapiens) ^UniProt
- Nociceptin receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

des(cyclopropylmethyl)buprenorphine | n-desalkylbuprenorphine | norbuprenorphine

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

HIV (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 1
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue